Show simple item record

dc.contributor.authorDu, Y
dc.contributor.authorCarrio, I
dc.contributor.authorDe Vincentis, G
dc.contributor.authorFanti, S
dc.contributor.authorIlhan, H
dc.contributor.authorMommsen, C
dc.contributor.authorNitzsche, E
dc.contributor.authorSundram, F
dc.contributor.authorVogel, W
dc.contributor.authorOyen, W
dc.contributor.authorLewington, V
dc.date.accessioned2017-07-05T11:10:57Z
dc.date.issued2017-09
dc.identifier.citationEuropean journal of nuclear medicine and molecular imaging, 2017, 44 (10), pp. 1671 - 1678
dc.identifier.issn1619-7070
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/685
dc.identifier.eissn1619-7089
dc.identifier.doi10.1007/s00259-017-3756-7
dc.description.abstractPurpose Radium Ra 223 dichloride (radium-223, Xofigo®) is the first targeted alpha therapy for patients with castration-resistant prostate cancer and symptomatic bone metastases. Radium-223 provides a new treatment option for this setting, but also necessitates a new treatment management approach. We provide straightforward and practical recommendations for European nuclear medicine centres to optimize radium-223 service provision.Methods An independent research consultancy agency observed radium-223 procedures and conducted interviews with all key staff members involved in radium-223 treatment delivery in 11 nuclear medicine centres across six countries (Germany, Italy, the Netherlands, Spain, Switzerland and the UK) experienced in administering radium-223. The findings were collated and discussed at a meeting of experts from these centres, during which key consensus recommendations were defined.Results The recommendations cover centre organization and preparation; patient referral; radium-223 ordering, preparation and disposal; radium-223 treatment delivery/administration; and patient experience. Guidance includes structured coordination and communication within centres and multidisciplinary teams, focusing on sharing best practice to provide high-quality, patient-centred care throughout the treatment pathway.Conclusions These expert recommendations are intended to complement existing management guidelines. Sharing best practice and experience will help nuclear medicine centres to optimize radium-223 service provision and improve patient care.
dc.formatPrint-Electronic
dc.format.extent1671 - 1678
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectHumans
dc.subjectNeoplasm Metastasis
dc.subjectRadium
dc.subjectPatient Selection
dc.subjectExpert Testimony
dc.subjectPatient Satisfaction
dc.subjectMale
dc.subjectProstatic Neoplasms, Castration-Resistant
dc.titlePractical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer.
dc.typeJournal Article
dcterms.dateAccepted2017-06-07
rioxxterms.versionofrecord10.1007/s00259-017-3756-7
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2017-09
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfEuropean journal of nuclear medicine and molecular imaging
pubs.issue10
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Molecular Imaging
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Molecular Imaging
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume44en_US
pubs.embargo.termsNo embargo
icr.researchteamTranslational Molecular Imagingen_US
dc.contributor.icrauthorOyen, Willem
dc.contributor.icrauthorMarsden,


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0